The much awaited decision of the ‘FDA’ in January this years had backed great appreciation across the globe. The Food and Drug Administration of US finally approved the Evotaz or atazanavir combination that is now being used in blend with various ARV’s effective in treating HIV-1. Industry experts eyeing the global and Chinese atazanavir industry say the approval comes as a great boost for manufacturers such as Bristol- Myers Squibb and Gilead Sciences that manufacturers Reyataz and Tybost. Experts believe that the drug would increase the drug levels of various ARV’s.
Gaging at such amendments in the atazanavir business, Prof Research Reports has added a report titled “Global and Chinese Atazanavir Industry." The report highlights the market share and size, opportunities, trends, value chain analysis, consumption volume and opportunities among various other factors spurring growth in atazanavir segment in China. The head of global market at Bristol- Myers Squibb, Murdo Gordon in a press release said “Evotaz increases the possibility of providing HIV suppression by combining reduced pill burden with a low rate of virologic failure and zero protease inhibitor mutations,"
The FDA has seconded the use of atazanavir and cobicistat to treat adults combating HIV infection. Medical professionals advocate Atazanavir/cobicistat as a fixed –dose blend tablets which comprises of around 300 mg and 150 mg atazanavir and cobicistat respectively. Murdo on FDA approval explained "We are pleased to provide physicians and patients with an important new option to treat HIV; atazanavir with cobicistat delivers sustained efficacy and safety through 48 weeks, as demonstrated through its rigorous clinical development plan, including a head-to-head Phase III trial."